EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances

Ayda Baghery Saghchy Khorasani, Nasim Hafezi, Mohammad-Javad Sanaei, Farideh Jafari-Raddani, Atieh Pourbagheri-Sigaroodi, Davood Bashash

Cell Biochemistry and Function · 2024

DOI: 10.1002/cbf.3998 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Biochemistry and Function, 2024. Verfasst von Ayda Baghery Saghchy Khorasani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinase, Breast Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 174 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most commonly diagnosed cancer and the leading cause of cancer mortality in women. As the phosphatidylinositol 3‐kinase (PI3K) signaling pathway is involved in a wide range of physiological functions of cells including growth, proliferation, motility, and angiogenesis, any alteration in this axis could induce oncogenic features; therefore, numerous preclinical and clinical studies assessed agents able to inhibit the components of this pathway in BC patients. To the best of our knowledge, this is the first study that analyzed all the registered clinical trials investigating safety and efficacy of the PI3K/AKT/mTOR axis inhibitors in BC. Of note, we found that the trends of PI3K inhibitors in recent years were superior as compared with the inhibitors of either AKT or mTOR. However, most of the trials entering phase III and IV used mTOR inhibitors (majorly Everolimus) followed by PI3K inhibitors (majorly Alpelisib) leading to the FDA approval of these drugs in the BC context. Despite favorable efficacies, our analysis shows that the majority of trials are utilizing PI3K pathway inhibitors in combination with hormone therapy and chemotherapy; implying monotherapy cannot yield huge clinical benefits, at least partly, due to the activation of compensatory mechanisms. To emphasize the beneficial effects of these inhibitors in combined‐modal strategies, we also reviewed recent studies which investigated the conjugation of nanocarriers with PI3K inhibitors to reduce harmful toxicities, increase the local concentration, and improve their efficacies in the context of BC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylinositol 3-KinaseBreast NeoplasmsHumansFemaleProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesSignal TransductionTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase Inhibitors

Stichwörter der Autor:innen

AKTPI3Kbreast cancerclinical trialmTOR

Substanzen

Phosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
  • Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran.
  • Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Khorasani, A. B. S., Hafezi, N., Sanaei, M. J., Jafari-Raddani, F., Pourbagheri-Sigaroodi, A., & Bashash, D. (2024). The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.3998

Vancouver

Khorasani ABS, Hafezi N, Sanaei MJ, Jafari-Raddani F, Pourbagheri-Sigaroodi A, Bashash D. The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances. Cell Biochemistry and Function. 2024. doi:10.1002/cbf.3998

BibTeX
@article{Khorasani2024,
  author = {Khorasani, Ayda Baghery Saghchy and Hafezi, Nasim and Sanaei, Mohammad-Javad and Jafari-Raddani, Farideh and Pourbagheri-Sigaroodi, Atieh and Bashash, Davood},
  title = {The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances},
  journal = {Cell Biochemistry and Function},
  year = {2024},
  doi = {10.1002/cbf.3998}
}
Kostenlos starten →